| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/01/2010 | US7728004 crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder |
| 06/01/2010 | US7728003 8-Indan-5-yl-2-[4-(4-methyl-piperazin-1-yl)-propylamino]-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid amide; antiinflammatory, anticarcinogenic agent, cardiovascular disease; glomerulonephritis, immune nephritis, rheumatoid arthritis, asthma, pancreatitis, HIV infection, psoriasis |
| 06/01/2010 | US7728002 peroxisome proliferator activated receptors modulators such as 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-butanoic acid, methyl ester, used for treating atherosclerosis, myocardial infarction, hypertension and cerebral vascular diseases |
| 06/01/2010 | US7728001 Opioid receptor ligands and methods for their preparation |
| 06/01/2010 | US7728000 compounds which intercalate between DNA base pairs, resulting in an interruption of transcription, replication and/or topoisomerase activity; antiproliferative and antitumor agents |
| 06/01/2010 | US7727999 substituted 1,3,8-triaza-spiro[4.5]decan-2-one compounds, used as selective serotonin receptor antagonists, used rfor the treatment of schizophrenia, psychosis, headaches, hypertension, thrombosis, vasospasm, depression, anxiety, sleep disorders and appetite disorders |
| 06/01/2010 | US7727998 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 06/01/2010 | US7727997 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 06/01/2010 | US7727996 Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 06/01/2010 | US7727995 Antiherpes drug combinations |
| 06/01/2010 | US7727994 administering adenosine receptor antagonist; side effect reduction; Parkinson's disease |
| 06/01/2010 | US7727993 administering adenosine receptor antagonist with dopamine antagonist;; Parkinson's disease; side effect reduction; low dosage of dopamine |
| 06/01/2010 | US7727992 2-(3-Ethyl-ureido)-6-pyridin-3-yl-3H-benzoimidazole-4-carboxylic acid methyl ester; for treating bacterial infections in mammals; useful in treating or lessening severity of urinary tract infections, pneumonia, prostatitis, skin and soft tissue infections, intra-abdominal infections |
| 06/01/2010 | US7727991 Substituted melanocortin receptor-specific single acyl piperazine compounds |
| 06/01/2010 | US7727990 Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions |
| 06/01/2010 | US7727989 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments |
| 06/01/2010 | US7727988 such as 1-(3-{(1S,5R)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hex-3-yl}propyl)- 2,4(1H,3H)-pyrimidinedione, used in therapy, as modulators of dopamine D3 receptors, to treat drug dependency or as antipsychotic agents |
| 06/01/2010 | US7727987 useful as intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations; for treatment of neurological disorders such as parkinsonism and atypical phenylketonuria |
| 06/01/2010 | US7727985 For therapy of inflammatory disease and cancer |
| 06/01/2010 | US7727984 Medicaments for the treatment of chronic obstructive pulmonary disease |
| 06/01/2010 | US7727983 Oxadiazoanthracene compounds for the treatment of diabetes |
| 06/01/2010 | US7727982 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility |
| 06/01/2010 | US7727981 monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders |
| 06/01/2010 | US7727980 Tricyclic androgen receptor modulator compounds and methods |
| 06/01/2010 | US7727979 Guanidine derivatives and their use as neuropeptide FF receptor antagonists |
| 06/01/2010 | US7727978 Reduce a racemic compound with enzymatic reductase, ketoreductase produced by microorganism Pichia, Hansenula, Candida or Rhodotorula; diabetes, hyperglycemia, obesity, dislipidemia, hypertension, cognitive impairment, rheumatoid arthritis, osteoarthritis, glaucoma |
| 06/01/2010 | US7727977 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |
| 06/01/2010 | US7727976 achieving prolonged therapeutic or prophylactic blood concentrations of a drug or active metabolite ; transportating through intestine walls |
| 06/01/2010 | US7727975 prepared by an enzymatic reaction by pectinesterase to cross-link pectin with starch, both of which are natural and belonging to GRAS (generally recognized as safe) substances; useful in food products, including nutritional supplements, to reduce calorie content and increase fiber content |
| 06/01/2010 | US7727974 Methods of reducing the severity of mucositis |
| 06/01/2010 | US7727973 Lipid A-type compound and composition containing it |
| 06/01/2010 | US7727972 Methods for determining absorption of cobalamin or analogues thereof |
| 06/01/2010 | US7727970 Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virus |
| 06/01/2010 | US7727969 Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| 06/01/2010 | US7727968 Administering anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog for therapy of acute leukemia or myelodysplastic syndrome |
| 06/01/2010 | US7727967 oximino(dihalophenyl)acetonitriles and anthracycline compound (adriamycin, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin) mixture; synergistic effect; reducing cardiotoxicity anticarcinogenic anthracycline drugs; inhibiting enzyme(s) that catalyze conversion to anthracycline metabolites |
| 06/01/2010 | US7727966 Slow to settle; easy to resuspend |
| 06/01/2010 | US7727965 C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same |
| 06/01/2010 | US7727964 Peptides substituted with a functional group that reacts with an active site residue of the targeted protease, e.g., Cyclohexylglycine BoroAla, and compounds that can hydrolyzed to produce them; improved specificity for regulating glucose metabolism |
| 06/01/2010 | US7727962 Powder comprising new compositions of oligosaccharides and methods for their preparation |
| 06/01/2010 | US7727961 Antioxidant constituents |
| 06/01/2010 | US7727958 Pharmaceutical formulation |
| 06/01/2010 | US7727955 For the treatment of infantile colics; gastrointestinal disorders; neurokinin A; N alpha [N alpha (benzo[b]thiophenyl-2-ylcarbonyl)-1-aminocyclopentane-1-carbonyl]-D-phenylalanine-N-[3(morpholin-4-yl)propyl]amide; infant foods |
| 06/01/2010 | US7727731 Potent, selective and non toxic c-kit inhibitors |
| 06/01/2010 | US7727712 Having an immunostimulatory sequence comprising the sequence 5'-C, G-3', wherein an HBV antigen is not administered in conjunction with administration of said nucleotide; for treatment of subject with hepatitis B virus |
| 06/01/2010 | US7727556 Granulation; compaction; rapid dissolution upon contact with physiological solvents such as water, saliva or gastrointestinal fluids |
| 06/01/2010 | US7727553 Multilayer composite; polymeric binder |
| 06/01/2010 | US7727548 Medicine stability; solubility in an oral cavity, and does not have uncomfortable tastes |
| 06/01/2010 | US7727547 Tissue-adhesive formulations |
| 06/01/2010 | US7727546 Nutrient system for individualized responsive dosing regimens |
| 06/01/2010 | US7727544 treatment and/or prevention of myopia utilizing energy sorce to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue; administered via a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane |
| 06/01/2010 | US7727537 Stabilized compositions for topical administration and methods of making same |
| 06/01/2010 | US7727536 EG-VEGF nucleic acids and polypeptides and methods of use |
| 06/01/2010 | US7727530 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody |
| 06/01/2010 | US7727528 Tumor necrosis factor receptor 1 specific immunoglobulins for targeted immaging and treatment and diagnosis of cell proliferative and autoimmune disorders |
| 06/01/2010 | US7727527 Anti-NGF antibodies for the therapeutic treatments |
| 06/01/2010 | US7727524 Low sodium liquid seasoning with anti-hypertensive activity |
| 06/01/2010 | US7727521 Method of ameliorating multi-organ failure resulting from ischemic reperfusion injury |
| 06/01/2010 | US7727517 Stabilized brood pheromone for manipulating the behavior and physiology of honey bees |
| 06/01/2010 | US7727466 test film made of water soluble two polymers, one having high molecular weight and the other having low molecular weight such as hydroxypropyl cellulose, hydroxymethyl propyl cellulose; for detecting chorionic gonadotropin, glucose, prostate specific antigen, metabolites; pesticides; or toxin; monolayer |
| 06/01/2010 | US7727275 Drug-delivery endovascular stent and method of forming the same |
| 06/01/2010 | CA2572607C Epimerisation of allylic alcohols |
| 06/01/2010 | CA2553915C 3(2h)-pyridazinone compounds as vascular intimal hyperplasia inhibitor |
| 06/01/2010 | CA2543640C Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |
| 06/01/2010 | CA2525867C Natural compounds and their derivatives for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications |
| 06/01/2010 | CA2515841C Novel 2-pyridine carboxamide derivatives |
| 06/01/2010 | CA2509775C Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers |
| 06/01/2010 | CA2490120C Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 06/01/2010 | CA2481217C Process for preparing acid salts of gemifloxacin |
| 06/01/2010 | CA2462745C Method of doping organic semi-conductors with quinonediimine derivatives and the dopand thereof |
| 06/01/2010 | CA2457965C Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| 06/01/2010 | CA2455595C Compositions of yeast cell walls and mannanoligosaccharides for control of coccidiosis |
| 06/01/2010 | CA2448737C Viral polymerase inhibitors |
| 06/01/2010 | CA2443456C Novel atisane compounds and use thereof |
| 06/01/2010 | CA2442049C Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist |
| 06/01/2010 | CA2440699C Compounds for treating inflammatory diseases |
| 06/01/2010 | CA2440680C Steroids as agonists for fxr |
| 06/01/2010 | CA2428817C Copolyvidone-containing preparation |
| 06/01/2010 | CA2427030C Fatigue recovering or fatigue preventive agent for central nervous system and food for fatigue recovery or fatigue prevention |
| 06/01/2010 | CA2426625C Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 06/01/2010 | CA2424501C New crystalline form of cefdinir |
| 06/01/2010 | CA2423007C Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients |
| 06/01/2010 | CA2420055C Fibrinogen-lowering agent |
| 06/01/2010 | CA2415169C Novel c-4 substituted retinoids |
| 06/01/2010 | CA2411205C Method of preparing an unsaturated fatty acid dry concentrate |
| 06/01/2010 | CA2409827C Arylmethylamine derivatives for use as tryptase inhibitors |
| 06/01/2010 | CA2403711C Methods of producing a terminally sterilized topical patch preparation |
| 06/01/2010 | CA2400626C Estrogen receptor modulators |
| 06/01/2010 | CA2388237C Treatment of osteoporosis |
| 06/01/2010 | CA2374958C Compositions normalizing circadian rhythm |
| 06/01/2010 | CA2366750C (e)-styryl sulfone anticancer agents |
| 06/01/2010 | CA2361552C Drug for alleviating migraine |
| 06/01/2010 | CA2352524C Aromatic heterocyclic compounds as antiinflammatory agents |
| 06/01/2010 | CA2336879C Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients |
| 06/01/2010 | CA2221495C Methods and uses for apoptin |
| 06/01/2010 | CA2176249C Aerosol drug formulations for use with non-cfc propellants |
| 06/01/2010 | CA2157427C Oxazoloquinolinone derivatives, their preparation and their therapeutic application |
| 05/27/2010 | WO2010060088A2 Pathways to generate hair cells |
| 05/27/2010 | WO2010060070A2 Indolinone modulators of dopamine receptor |
| 05/27/2010 | WO2010060041A2 Phenylalanine amide inhibitors of atp-sensitive potassium channels |